AU2018255489B2 - CD 14 antagonist antibodies for treating neurodegenerative diseases - Google Patents
CD 14 antagonist antibodies for treating neurodegenerative diseases Download PDFInfo
- Publication number
- AU2018255489B2 AU2018255489B2 AU2018255489A AU2018255489A AU2018255489B2 AU 2018255489 B2 AU2018255489 B2 AU 2018255489B2 AU 2018255489 A AU2018255489 A AU 2018255489A AU 2018255489 A AU2018255489 A AU 2018255489A AU 2018255489 B2 AU2018255489 B2 AU 2018255489B2
- Authority
- AU
- Australia
- Prior art keywords
- ser
- antibody
- sequence
- seq
- pro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017901462 | 2017-04-21 | ||
| AU2017901462A AU2017901462A0 (en) | 2017-04-21 | Agents for treating or preventing motor neurone disease and uses therefor | |
| AU2018900762 | 2018-03-08 | ||
| AU2018900762A AU2018900762A0 (en) | 2018-03-08 | “agents for treating disease and uses therefor” | |
| PCT/AU2018/050357 WO2018191786A1 (en) | 2017-04-21 | 2018-04-20 | Cd 14 antagonist antibodies for treating neurodegenerative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2018255489A1 AU2018255489A1 (en) | 2019-11-07 |
| AU2018255489B2 true AU2018255489B2 (en) | 2024-06-13 |
Family
ID=63855469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018255489A Active AU2018255489B2 (en) | 2017-04-21 | 2018-04-20 | CD 14 antagonist antibodies for treating neurodegenerative diseases |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20200148780A1 (https=) |
| EP (1) | EP3612566A4 (https=) |
| JP (2) | JP2020517740A (https=) |
| KR (1) | KR20200015477A (https=) |
| CN (1) | CN110831975A (https=) |
| AU (1) | AU2018255489B2 (https=) |
| IL (2) | IL309046B2 (https=) |
| WO (1) | WO2018191786A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019264996A1 (en) * | 2018-05-10 | 2020-11-26 | The Methodist Hospital | Methods for prognosis and management of disease |
| TWI809147B (zh) | 2018-07-13 | 2023-07-21 | 美商阿列克特有限責任公司 | 抗分揀蛋白抗體及其使用方法 |
| US20200392229A1 (en) * | 2019-06-11 | 2020-12-17 | Alector Llc | Methods of use of anti-sortilin antibodies |
| WO2021016601A1 (en) | 2019-07-25 | 2021-01-28 | Implicit Bioscience Limited | Methods and agents for treating acute neuroinflammatory injury |
| MX2022010006A (es) * | 2020-02-13 | 2022-09-19 | Prilenia Neurotherapeutics Ltd | Terapia combinada para el tratamiento de la amiotrofica lateral con pridopidina y otro agente activo. |
| WO2021253335A1 (zh) * | 2020-06-18 | 2021-12-23 | 深圳迈瑞生物医疗电子股份有限公司 | 抗可溶性cd14亚型抗体、试剂盒及其应用 |
| AU2021339468A1 (en) * | 2020-09-10 | 2023-03-30 | Implicit Bioscience Limited | Therapeutic methods and agents for the treatment of myocardial infarction |
| AU2021356298A1 (en) | 2020-10-07 | 2023-05-04 | Line 6 Biotechnology, Inc | Methods and agents for the treatment of ocular disease |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| CN117031014A (zh) * | 2023-08-14 | 2023-11-10 | 陕西脉元生物科技有限公司 | 抗matr3自身抗体的试剂在制备检测神经系统自身免疫疾病的产品中的应用及试剂盒 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| CN118290585B (zh) * | 2024-06-04 | 2024-08-30 | 苏州为度生物技术有限公司天津分公司 | 一种抗人cd14工程抗体及应用 |
| CN120399098B (zh) * | 2025-07-03 | 2025-09-16 | 上海玄言生物科技有限公司 | 抗cd14抗体-il-15超级激动剂融合蛋白及其制法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI920450A7 (fi) * | 1989-08-01 | 1992-01-31 | Scripps Clinic And Res Foundation | Menetelmiä ja koostumuksia verenmyrkytyksen oireiden estämiseksi |
| ATE335072T1 (de) | 1993-05-28 | 2006-08-15 | Scripps Research Inst | Methoden für inhibition der cd14-abhängigen zellaktivierung |
| EP0792162B1 (en) * | 1994-09-16 | 2005-11-09 | The Scripps Research Institute | Use of antibodies to block the effects of gram-positive bacteria and mycobacteria |
| US7264967B2 (en) | 2000-11-22 | 2007-09-04 | Mochida Pharmaceutical Co., Ltd. | Anti-CD14 monoclonal antibody having effect of inhibiting CD14/TLR binding |
| EP1819829A1 (en) | 2004-12-08 | 2007-08-22 | ICOS Corporation | Recombinant method for making multimeric proteins |
| US20090181008A1 (en) * | 2005-11-10 | 2009-07-16 | Satoris, Inc. | Methods of treating alzheimer's disease |
| KR101256837B1 (ko) * | 2009-03-09 | 2013-04-22 | 경북대학교 산학협력단 | 가용성 ｃｄ１４의 파킨슨 병 진단 및 치료용 용도 |
| CA2789963C (en) * | 2010-02-26 | 2019-09-03 | Bioarctic Neuroscience Ab | Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies |
| WO2018165720A1 (en) * | 2017-03-17 | 2018-09-20 | Implicit Bioscience Pty Ltd | Agents for treating or preventing viral infections and uses therefor |
| AU2019264996A1 (en) * | 2018-05-10 | 2020-11-26 | The Methodist Hospital | Methods for prognosis and management of disease |
-
2018
- 2018-04-20 EP EP18788123.0A patent/EP3612566A4/en active Pending
- 2018-04-20 US US16/606,727 patent/US20200148780A1/en not_active Abandoned
- 2018-04-20 CN CN201880040765.4A patent/CN110831975A/zh active Pending
- 2018-04-20 AU AU2018255489A patent/AU2018255489B2/en active Active
- 2018-04-20 JP JP2020507722A patent/JP2020517740A/ja active Pending
- 2018-04-20 KR KR1020197033198A patent/KR20200015477A/ko not_active Ceased
- 2018-04-20 WO PCT/AU2018/050357 patent/WO2018191786A1/en not_active Ceased
- 2018-04-20 IL IL309046A patent/IL309046B2/en unknown
- 2018-04-20 IL IL270097A patent/IL270097B2/en unknown
-
2021
- 2021-09-23 US US17/483,517 patent/US12297287B2/en active Active
-
2023
- 2023-04-13 JP JP2023065903A patent/JP2023090751A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12297287B2 (en) | 2025-05-13 |
| IL309046B1 (en) | 2024-11-01 |
| IL309046B2 (en) | 2025-03-01 |
| WO2018191786A1 (en) | 2018-10-25 |
| IL270097B1 (en) | 2024-01-01 |
| US20200148780A1 (en) | 2020-05-14 |
| US20220010025A1 (en) | 2022-01-13 |
| JP2020517740A (ja) | 2020-06-18 |
| IL270097A (https=) | 2019-12-31 |
| AU2018255489A1 (en) | 2019-11-07 |
| EP3612566A1 (en) | 2020-02-26 |
| IL309046A (en) | 2024-02-01 |
| KR20200015477A (ko) | 2020-02-12 |
| CN110831975A (zh) | 2020-02-21 |
| EP3612566A4 (en) | 2021-03-03 |
| IL270097B2 (en) | 2024-05-01 |
| JP2023090751A (ja) | 2023-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12297287B2 (en) | CD14 antagonist antibodies for treating neurodegenerative diseases | |
| JP7554247B2 (ja) | 抗ｔｒｅｍ２抗体及びその使用方法 | |
| KR20230005848A (ko) | 항-trem2 항체의 사용 방법 | |
| US12258390B2 (en) | Methods and agents for the treatment of ocular disease | |
| EP3082863B1 (en) | Alpha-enolase specific antibodies and method of use in immune diseases | |
| KR20230116850A (ko) | Trem2 작용제 바이오마커 및 이의 사용 방법 | |
| US10604566B2 (en) | Antagonists of IL-17C for the treatment and/or prevention of atopic dermatitis | |
| US20220340687A1 (en) | Methods of treatment using omalizumab | |
| US20250186439A1 (en) | Pyk2 inhibition modulates immune cell function | |
| HK1168112A (en) | Treatment for multiple sclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HB | Alteration of name in register |
Owner name: IMPLICIT BIOSCIENCE LIMITED Free format text: FORMER NAME(S): IMPLICIT BIOSCIENCE PTY LTD |
|
| FGA | Letters patent sealed or granted (standard patent) |